Literature DB >> 25511161

Canadian Society of Nephrology commentary on the KDIGO clinical practice guideline for CKD evaluation and management.

Ayub Akbari1, Catherine M Clase2, Phil Acott3, Marisa Battistella4, Aminu Bello5, Patrick Feltmate6, Allan Grill7, Meena Karsanji8, Paul Komenda9, Francois Madore10, Braden J Manns11, Sara Mahdavi12, Reem A Mustafa13, Andrew Smyth14, E Sohani Welcher15.   

Abstract

We congratulate the KDIGO (Kidney Disease: Improving Global Outcomes) work group on their comprehensive work in a broad subject area and agreed with many of the recommendations in their clinical practice guideline on the evaluation and management of chronic kidney disease. We concur with the KDIGO definitions and classification of kidney disease and welcome the addition of albuminuria categories at all levels of glomerular filtration rate (GFR), the terminology of G categories rather than stages to describe level of GFR, the division of former stage 3 into new G categories 3a and 3b, and the addition of the underlying diagnosis. We agree with the use of the heat map to illustrate the relative contributions of low GFR and albuminuria to cardiovascular and renal risk, though we thought that the highest risk category was too broad, including as it does people at disparate levels of risk. We add an albuminuria category A4 for nephrotic-range proteinuria and D and T categories for patients on dialysis or with a functioning renal transplant. We recommend target blood pressure of 140/90mm Hg regardless of diabetes or proteinuria, and against the combination of angiotensin receptor blockers with angiotensin-converting enzyme inhibitors. We recommend against routine protein restriction. We concur on individualization of hemoglobin A1c targets. We do not agree with routine restriction of sodium intake to <2g/d, instead suggesting reduction of sodium intake in those with high intake (>3.3g/d). We suggest screening for anemia only when GFR is <30mL/min/1.73m(2). We recognize the absence of evidence on appropriate phosphate targets and methods of achieving them and do not agree with suggestions in this area. In drug dosing, we agree with the recommendation of using absolute clearance (ie, milliliters per minute), calculated from the patient's estimated GFR (which is normalized to 1.73m(2)) and the patient's actual anthropomorphic body surface area. We agree with referral to a nephrologist when GFR is <30mL/min/1.73m(2) (and for many other scenarios), but suggest urine albumin-creatinine ratio > 60mg/mmol or proteinuria with protein excretion > 1g/d as the referral threshold for proteinuria.
Copyright © 2015 National Kidney Foundation, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Canadian Society of Nephrology (CSN); Estimated glomerular filtration rate (eGFR); Kidney Disease: Improving Global Outcomes (KDIGO); albuminuria; chronic kidney disease (CKD) staging; clinical practice guideline; kidney disease progression

Mesh:

Year:  2014        PMID: 25511161     DOI: 10.1053/j.ajkd.2014.10.013

Source DB:  PubMed          Journal:  Am J Kidney Dis        ISSN: 0272-6386            Impact factor:   8.860


  45 in total

1.  Can we predict the development of serious adverse events (SAEs) and early treatment termination in elderly non-small cell lung cancer (NSCLC) patients receiving platinum-based chemotherapy?

Authors:  Toshio Kato; Masahiro Morise; Masahiko Ando; Eiji Kojima; Tomohiko Ogasawara; Ryujiro Suzuki; Joe Shindoh; Masami Matsumoto; Yasuteru Sugino; Masahiro Ogawa; Yasuhiro Nozaki; Tetsunari Hase; Masashi Kondo; Hiroshi Saito; Yoshinori Hasegawa
Journal:  J Cancer Res Clin Oncol       Date:  2016-05-11       Impact factor: 4.553

Review 2.  Approach to the detection and management of chronic kidney disease: What primary care providers need to know.

Authors:  Allan K Grill; Scott Brimble
Journal:  Can Fam Physician       Date:  2018-10       Impact factor: 3.275

3.  Beclin-1 regulates cigarette smoke-induced kidney injury in a murine model of chronic obstructive pulmonary disease.

Authors:  Maria A Pabón; Edwin Patino; Divya Bhatia; Joselyn Rojas-Quintero; Kevin C Ma; Eli J Finkelsztein; Juan C Osorio; Faryal Malick; Francesca Polverino; Caroline A Owen; Stefan W Ryter; Augustine Mk Choi; Suzanne M Cloonan; Mary E Choi
Journal:  JCI Insight       Date:  2018-09-20

Review 4.  Update on blood pressure control and renal outcomes in diabetes mellitus.

Authors:  Mark Henry Joven; Robert J Anderson
Journal:  Curr Diab Rep       Date:  2015-07       Impact factor: 4.810

5.  Prognostic implications of preoperative chronic kidney disease and anemia in patients undergoing coronary artery bypass graft surgery.

Authors:  Takuya Ogami; Yuya Matsue; Ryo Kawasumi; Hiroaki Tanabe
Journal:  Surg Today       Date:  2016-06-20       Impact factor: 2.549

6.  Interlaboratory Variability in Plasma Creatinine Measurement and the Relation with Estimated Glomerular Filtration Rate and Chronic Kidney Disease Diagnosis.

Authors:  Elizabeth Lee; Christine P Collier; Christine A White
Journal:  Clin J Am Soc Nephrol       Date:  2016-11-08       Impact factor: 8.237

7.  Nationwide multicenter kidney biopsy study of Japanese patients with hypertensive nephrosclerosis.

Authors:  Kengo Furuichi; Miho Shimizu; Yukio Yuzawa; Akinori Hara; Tadashi Toyama; Hiroshi Kitamura; Yoshiki Suzuki; Hiroshi Sato; Noriko Uesugi; Yoshifumi Ubara; Junichi Hoshino; Satoshi Hisano; Yoshihiko Ueda; Shinichi Nishi; Hitoshi Yokoyama; Tomoya Nishino; Kentaro Kohagura; Daisuke Ogawa; Koki Mise; Yugo Shibagaki; Kenjiro Kimura; Masakazu Haneda; Hirofumi Makino; Seiichi Matsuo; Takashi Wada
Journal:  Clin Exp Nephrol       Date:  2017-11-11       Impact factor: 2.801

8.  Higher protein intake is associated with increased risk for incident end-stage renal disease among blacks with diabetes in the Southern Community Cohort Study.

Authors:  R Malhotra; K L Cavanaugh; W J Blot; T A Ikizler; L Lipworth; E K Kabagambe
Journal:  Nutr Metab Cardiovasc Dis       Date:  2016-07-21       Impact factor: 4.222

9.  The See Kidney Disease Targeted Screening Program for CKD.

Authors:  Lauren E Galbraith; Paul E Ronksley; Lianne J Barnieh; Joanne Kappel; Braden J Manns; Susan M Samuel; Min Jun; Rob Weaver; Nadine Valk; Brenda R Hemmelgarn
Journal:  Clin J Am Soc Nephrol       Date:  2016-05-19       Impact factor: 8.237

Review 10.  The gut microbiome, diet, and links to cardiometabolic and chronic disorders.

Authors:  Judith Aron-Wisnewsky; Karine Clément
Journal:  Nat Rev Nephrol       Date:  2015-11-30       Impact factor: 28.314

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.